Effect of adherence to evidence-based therapy after acute myocardial infarction on all-cause mortality

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 10, 2015, Pages 1093-1104

  Hamood, Hatem ^a,b   Hamood, Rola ^c   Green, Manfred S ^c   Almog, Ronit ^c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Leumit Health Care Services   (Israel)

^c UNIVERSITY OF HAIFA   (Israel)

Author keywords

Medication adherence; Mortality; Myocardial infarction; Pharmacoepidemiology; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOTONIC AGENT;

ACUTE HEART INFARCTION; ADULT; ALL CAUSE MORTALITY; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH CARE ORGANIZATION; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; ISRAEL; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVOR; TREATMENT DURATION; AGED; MIDDLE AGED; MYOCARDIAL INFARCTION; PROCEDURES; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TRENDS;

AGED; CARDIOTONIC AGENTS; COHORT STUDIES; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84942823046     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3840     Document Type: Article

References (37)

1. Goldschmidt R. Heart diseases in Israel: prevalence, treatment and mortality prevention [Article in Hebrew]. https://www.knesset.gov.il/mmm/data/pdf/m01986.pdf (accessed 10 March 2013).
2. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management Of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50(7): e1-e157.
3. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110(9): e82-e292.
4. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008; 29(23): 2909-2945.
5. Akincigil A, Bowblis JR, Levin C, et al. Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction. J Gen Intern Med 2008; 23(2): 115-121.
6. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119(23): 3028-3035.
7. Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004; 19(6): 638-645.
8. Anfanger S, Grotto I, Reuveni H, et al. Adherence to secondary prevention guidelines after myocardial infarction is still poor. Conference abstract. ACSIS 2011.
9. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008; 30(11): 2167-2179.
10. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 2007; 116(7): 737-744.
11. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006; 113(2): 203-212.
12. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297(2): 177-186.
13. Shalev V, Chodick G, Silber H, et al. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009; 169(3): 260-268.
14. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88(3): 229-233.
15. Lai EJ, Grubisic M, Palepu A, et al. Cardiac medication prescribing and adherence after acute myocardial infarction in Chinese and South Asian Canadian patients. BMC Cardiovasc Disord 2011; 11: 56-63.
16. Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009; 25(9): 2303-2310.
17. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50(1): 105-116.
18. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353(5): 487-497.
19. Perreault S, Blais L, Dragomir A, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 2005; 61(9): 667-674.
20. Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 2002; 40(9): 1589-1595.
21. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34(38): 2940-2948.
22. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166(17): 1842-1847.
23. Burkhart PV, Sabate E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh 2003; 35(3): 207.
24. Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001; 26(5): 331-342.
25. ACSIS. Survey findings and temporal trends 2000-2010. ACSIS 2010.
26. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71-86.
27. Tuppin P, Neumann A, Danchin N, et al. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis 2010; 103(6-7): 363-375.
28. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282(24): 2340-2346.
29. Abramson J, Wright JM. Are lipid-lowering guidelines evidence-based? Lancet 2007; 369(9557): 168-169.
30. Mickley H, Eiskjaer H, Botker HE. Is an additional post-myocardial infarction beta-blocker trial required in the era of early revascularization? Eur Heart J 2004; 25(1): 96-97.
31. Lenzi J, Rucci P, Castaldinie I, et al. Does age modify the relationship between adherence to secondary prevention medications and mortality after acute myocardial infarction? A nested case-control study. Eur J Clin Pharmacol 2015; 71(2): 243-250.
32. Yusuf S, Anand S, Avezum A, Jr, et al. Treatment for acute myocardial infarction. Overview of randomized clinical trials. Eur Heart J 1996; 17(Suppl F): 16-29.
33. Papageorgiou N, Tousoulis D, Antoniades C, et al. The impact of statin administration in acute coronary syndromes. Hellenic J Cardiol 2010; 51(3): 250-261.
34. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008; 117(8): 1028-1036.
35. Grymonpre R, Cheang M, Fraser M, et al. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 2006; 44(5): 471-477.
36. Wamala S, Merlo J, Bostrom G, et al. Socioeconomic disadvantage and primary non-adherence with medication in Sweden. Int J Qual Health Care 2007; 19(3): 134-140.
37. Johnson ES, Mozaffari E. Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. Am J Manag Care 2002; 8(10 Suppl): S249-54.